Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
Public ClinicalTrials.gov record NCT00535145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the treatment of patients with schizophrenia or schizoaffective disorder and liver disease.
Study identification
- NCT ID
- NCT00535145
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 121 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2007 (Type not available)
- Primary completion
- Feb 2009 (Actual)
- Completion
- Feb 2009 (Actual)
- Last update posted
- Jul 25, 2014
2007 – 2009
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Cerritos | California | — | — |
| Not listed | Chino | California | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Huntington Beach | California | — | — |
| Not listed | Santa Ana | California | — | — |
| Not listed | Torrance | California | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Hollywood | Florida | — | — |
| Not listed | Kissimmee | Florida | — | — |
| Not listed | Lake Charles | Louisiana | — | — |
| Not listed | Flowood | Mississippi | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Clementon | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Staten Island | New York | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Norristown | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Sioux Falls | South Dakota | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | White River Junction | Vermont | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00535145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2014 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00535145 live on ClinicalTrials.gov.